Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17538471 | 0.86 | VCAM1 (0.44) | VCAM1MAPTALDH1A1HTTTDP1 | |
| SCHEMBL19606264 | 0.85 | MAPT (0.50) | VCAM1MAPTALDH1A1HTTTDP1 | |
| SCHEMBL31200186 | 0.84 | VCAM1 (0.47) | VCAM1MAPTALDH1A1HTTTDP1 | |
| SCHEMBL57107 | 0.84 | VCAM1 (0.47) | VCAM1MAPTALDH1A1HTTTDP1 | |
| Potassium Ion SCHEMBL5158030 | 0.81 | VCAM1 (0.45) | VCAM1MAPTALDH1A1HTTTDP1 | |
| Acetonitrile SCHEMBL9863169 | 0.81 | TDP1 (0.47) | VCAM1MAPTALDH1A1TDP1POLB | |
| SCHEMBL4614436 | 0.80 | VCAM1 (0.47) | VCAM1MAPTALDH1A1HTTTDP1 | |
| SCHEMBL23524821 | 0.79 | GRIA1 (0.45) | VCAM1MAPTALDH1A1HTTTDP1 | |
| SCHEMBL22031625 | 0.79 | ALDH1A1 (0.45) | VCAM1MAPTALDH1A1HTTTDP1 | |
| SCHEMBL2241912 | 0.79 | VCAM1 (0.44) | VCAM1MAPTALDH1A1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4638420-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4565575-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Alivexis, Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| CN-119866333-A | KIT inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | 亚力维克希斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-113166156-B | Tyrosine kinase inhibitors, compositions and methods | 贝达药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-0556393-B1 | FUSED PYRAZINE DERIVATIVE | YAMANOUCHI PHARMA CO LTD (JP) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999026941-A1 | SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| CN-1041931-C | [1,2,4]triazolo[4,3-a]quinoxaline compounds, their preparation and use | NOVO NORDISK AS (DK) | 1999-02-03 | — | — | CN | disclosed |
| EP-0698024-B1 | [1,2,4]TRIAZOLO [4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1997-01-22 | — | — | EP | disclosed |
| US-5532236-A | TREATMENT OF PARKINSON'S DISEASE | NOVO NORDISK A/S (DK) | 1996-07-02 | — | — | US | disclosed |
| CN-1125446-A | [1,2,4]triazolo[4,3-a]quinoxaline compounds, their preparation and use | NOVO NORDISK AS (DK) | 1996-06-26 | — | — | CN | disclosed |
| EP-0698024-A1 | 1,2,4]TRIAZOLO 4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026746-A1 | [1,2,4]TRIAZOLO[4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-11-24 | — | — | WO | disclosed |
| US-5283244-A | Anticonvulsants, nervous system disorders | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-02-01 | — | — | US | disclosed |
| EP-0556393-A1 | FUSED PYRAZINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | VCAM1 1249/4885MAPT 2537/4885ALDH1A1 1030/4885 |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | FLI1, MCL1, SP1 | VCAM1 217/4885MAPT 4351/4885ALDH1A1 312/4885 |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KIT, LTK, HRH3 | VCAM1 923/4885MAPT 4268/4885ALDH1A1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.